ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$188.5M
Cash & Equivalents
$97.9M
Quarterly Burn Rate
$10,761M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PLOZASIRAN SODIUM
REDEMPLO |
APPROVED | Alpha 1-Antitrypsin Deficiency, Alzheimer Disease, Alzheimer Disease, Early Onset, Amyotrophic Lateral Sclerosis, Asthma, C3 Glomerulopathy, Chronic Hepatitis B, Chronic Obstructive Pulmonary Disease, Clear Cell Renal Cell Carcinoma, Cystic Fibrosis, Pulmonary, Diabetes Mellitus, Type 2, Dyslipidemias, Facio-Scapulo-Humeral Dystrophy, Familial Chylomicronemia, Familial Chylomicronemia Syndrome, Familial Hypercholesterolemia, Healthy, Healthy Adult Volunteers, Healthy Participants, Hepatitis B, Hepatitis B, Chronic, Hepatitis D, High Risk Severe Hypertriglyceridemia (SHTG), Homozygous Familial Hypercholesterolemia, Hyperlipidemia; Mixed, Hypertriglyceridemia, Idiopathic Pulmonary Fibrosis, IgA Nephropathy, Mixed Dyslipidemia, Myotonic Dystrophy 1, Non-alcoholic Steatohepatitis, Obesity, Severe Hypertriglyceridemia, Spinocerebellar Ataxia Type 2 |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer F... | PHASE3 | Active Not Recruiting | 1,550 |
| NCT03936361 | Statins In Intracerbral Hemorrhage | PHASE3 | Recruiting | 1,456 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.